LEUKAEMIA MICROENVIRONMENT & HIGH RISK CHILDHOOD LEUKAEMIA
With
Associate Professor Laurence Cheung
Curtin University
& Research Lead, Curtin Medical Research Institute,
Western Australia &
Research Lead,
The Kids Research Institute,
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Associate Professor Laurence Cheung is an exemplary pharmacist-scientist whose research is focused on improving outcomes in children with high-risk leukaemia.
He obtained his Bachelor of Pharmacy degree with First Class Honours from the Curtin University in 2000 and have been a registered pharmacist since 2001. In 2014, he completed the PhD studies at The Kids Research Institute Australia (The Kids) in the area of haematopoiesis and paediatric leukaemia.
He is now an Associate Professor at the Curtin Medical School as well as Curtin Medical Research Institute, and a Co-head of the Leukaemia Translational Research Laboratory at The Kids.
He has attracted over $8.7 million in research funding, including 16 awards as CIA (over $6.1 million). Assoc Prof Cheung was named the 2019 Cancer Council of WA Early Career Cancer Researcher of the Year and received the STEM Early Career Research Award at Curtin University in 2019.
Assoc Prof Cheung enjoys nurturing and motivating the next generation scientists and HDR students and he believes that the true success is about influencing others to achieve their own greatness.
He has supervised two PhD and one Masters students to completion, and is currently supervising 4 PhD students as a Primary Supervisor. In 2023, Assoc Prof Cheung received the Faulty of Health Sciences Teaching Excellence Individual Award for Honours, Postgraduate, or HDR supervision at Curtin University.
Funding sources include: Toby for Childhood Cancer, Cancer Council Western Australia, WA Government
Source: Supplied and adapted
https://orcid.org/0000-0001-6298-5288
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
